Triple-Negative Breast Cancer Treated With Mastectomy and Chemotherapy
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- Triple-negative.
- Sex
- Female
- Treatment
- surgery, reconstruction and chemotherapy
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- Modified radical mastectomy with immediate reconstruction was performed.
- Dose-dense doxorubicin and cyclophosphamide chemotherapy was given.
- Paclitaxel chemotherapy followed.
What happened, in summary
A 44-year-old woman had a history of triple-negative invasive ductal carcinoma in the upper outer quadrant of her left breast. The original tumor was classified T2N1. She underwent a modified radical mastectomy with immediate reconstruction. Final pathology showed a 2.8 cm invasive ductal carcinoma with one of 15 lymph nodes involved.
After surgery, she received dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel. She then remained free of a local recurrence for five years.
Five years later, she discovered a new mass beneath a supernumerary nipple at the inframammary fold. The new lesion had a different histology and receptor profile and was considered a separate primary cancer arising in accessory breast tissue rather than a recurrence of the original invasive ductal carcinoma. This distinction separated the first tumor’s triple-negative status, nodal involvement, mastectomy, and chemotherapy from the later tumor’s hormone-receptor expression and different treatment pathway. After treatment of both cancers, she was described as currently having no evidence of disease.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Triple-Negative Breast Cancer 161 stories
- Chemotherapy for Breast Cancer 726 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer